NorthWest Biotherapeutics Inc (NWBO)

[Horseb4CarT]

As long as we’re playing Duffy guessing games, I’m guessing the multiple purposes of helping with the SAP and perhaps contacts to help DCVax-L approval and thus strengthen the position of the combination trial with Keytruda, get an intimate view of NWBO and integration/synergy potential, and to better run the combination trials from Merck’s interests. Ultimately it would make him a better candidate to run Merck’s resulting integrated oncology program.

I agree that it was “cleaner and less provocative” to have Duffy as an NWBO employee rather than on assignment from Merck. It is also possible that Duffy was enticed to work for NWBO and later the idea of bringing him back emerged, but my hunch is it was planned and that could also tie into LP and Merck’s executive being together at ASCO.